A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)
Bayodé Roméo Adégbitè, Oscar Leonard Kaswaga, Hamu J. Mlyuka, Tim McHugh et al.
Journal
Trials
Topics
Tuberculosis Research and Epidemiology
article
A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB)
Bayodé Roméo Adégbitè, Oscar Leonard Kaswaga, Hamu J. Mlyuka, Tim McHugh, Jeremiah Kidola, Emmanuel Mpolya, Sloan Derek, Celso Khosa, Martin J. Boeree, Peter M. Mbelele, Benno Mbeya, Belinda Chriacus Nyaulingo, Alphonce Liyoyo, Stephen H Gillespie, Samwel Lwambura, Stellah G Mpagama, Wilber Sabiiti, Hadija Semvua, Leticia Wildner, Marriot Nliwasa
article en
Abstract
No abstract available for this paper.
Publication Tag
TrialsVol. 27(1)
Institutions
Ifakara Health Institute (TZ), Radboud University Nijmegen (NL), Muhimbili University of Health and Allied Sciences (TZ), University of St Andrews (GB), Kamuzu Central Hospital (MW), Radboud University Medical Center (NL), NHS Fife (GB), Centre de Recherche Médicales de Lambaréné (GA), Victoria Hospital (GB), Instituto Nacional de Saúde (MZ), Kilimanjaro Christian Medical Centre (TZ), UCL Biomedical Research Centre (GB), National Institute for Medical Research (TZ), Kamuzu University of Health Sciences (MW), University College London (GB), Nelson Mandela African Institution of Science and Technology (TZ)